Keywords: depomed, gets, exclusive, gabapentin, rights, says, acquired

Depomed gets exclusive gabapentin rights

Article | 29 September 2003

Print This

Depomed says it has acquired exclusive development and commercialization rights to Gabapentin GR, a novel formulation of the seizure and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in